Association between the Alu Insertion/Deletion Polymorphism in the Tissue-Type Plasminogen Activator Gene and Mirtazapine Response in Koreans with Major Depression

키워드

참고문헌 (48)

1. Jones KR, "Molecular cloning of a human gene that is a member of the nerve growth factor family", Proc Natl Acad Sci U S A, 87, pp.8060~8064 (1990)
2. Leibrock J, "Molecular cloning and expression of brain-derived neurotrophic factor", Nature, 341, pp.149~152 (1989)
3. Ventimiglia R, "The neurotrophins BDNF, NT-3 and NT-4", 5 promote survival and morphological and biochemical differentiation of striatal neurons in vitro, 1995, pp.7, 213~222
4. Fernandes BS, "Decreased peripheral brain-derived neurotrophic factor levels are a biomarker of disease activity in major psychiatric disorders: a comparative meta-analysis", Mol Psychiatry, 19, pp.750~751 (2014)
5. Polyakova M, "BDNF as a biomarker for successful treatment of mood disorders: a systematic & quantitative meta-analysis", J Affect Disord, 174, pp.432~440 (2015)
6. Roceri M, "Early maternal deprivation reduces the expression of BDNF and NMDA receptor subunits in rat hippocampus", Mol Psychiatry, 7, pp.609~616 (2002)
7. Smith MA, "Stress and glucocorticoids affect the expression of brain-derived neurotrophic factor and neurotrophin-3 mRNAs in the hippocampus", J Neurosci, 15(3 Pt 1), pp.1768~1777 (1995)
8. Martinowich K, "Interaction between BDNF and serotonin:role in mood disorders", Neuropsychopharmacology, 33, pp.73~83 (2008)
9. Altar CA, "Neurotrophins and depression", Trends Pharmacol Sci, 20, pp.59~61 (1999)
10. Duman RS, "Synaptic plasticity and mood disorders", Mol Psychiatry, 7(Suppl 1), pp.S29~S34 (2002)
11. Nestler EJ, "Preclinical models: status of basic research in depression", Biol Psychiatry, 52, pp.503~528 (2002)
12. Coyle JT, "Finding the intracellular signaling pathways affected by mood disorder treatments", Neuron, 38, pp.157~160 (2003)
13. Lee R, "Regulation of cell survival by secreted proneurotrophins", Science, 294, pp.1945~1948 (2001)
14. Pang PT, "Cleavage of proBDNF by tPA", plasmin is essential for long-term hippocampal plasticity, 2004, pp.306, 487~491
15. Seidah NG, "Cellular processing of the nerve growth factor precursor by the mammalian pro-protein convertases", Biochem J, 314(Pt 3), pp.951~960 (1996)
16. Nibuya M, "Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments", J Neurosci, 15, pp.7539~7547 (1995)
17. Russo-Neustadt A, "Exercise, antidepressant medications, and enhanced brain derived neurotrophic factor expression", Neuropsychopharmacology, 21, pp.679~682 (1999)
18. Pawlak R, "Tissue plasminogen activator in the amygdala is critical for stress-induced anxiety-like behavior", Nat Neurosci, 6, pp.168~174 (2003)
19. Pietraszek MH, "Fibrinolytic activity in depression and neurosis", Thromb Res, 63, pp.661~666 (1991)
20. Shi Y, "Plasma BDNF and tPA are associated with late-onset geriatric depression", Psychiatry Clin Neurosci, 64, pp.249~254 (2010)
21. Jörnvall H, "Differential proteolysis and evidence for a residue exchange in tissue plasminogen activator suggest possible association between two types of protein microheterogeneity", FEBS Lett, 156, pp.47~50 (1983)
22. Pennica D, "Cloning and expression of human tissue-type plasminogen activator cDNA in E. coli", Nature, 301, pp.214~221 (1983)
23. Yang-Feng TL, "Human tissue-type plasminogen activator gene located near chromosomal breakpoint in myeloproliferative disorder", Am J Hum Genet, 39, pp.79~87 (1986)
24. Degen SJ, "The human tissue plasminogen activator gene", J Biol Chem, 261, pp.6972~6985 (1986)
25. Ludwig M, "Allelic dimorphism in the human tissue-type plasminogen activator (TPA) gene as a result of an Alu insertion", deletion event, 1992, pp.88, 388~392
26. Tishkoff SA, "Distribution and frequency of a polymorphic Alu insertion at the plasminogen activator locus in humans", Hum Genet, 97, pp.759~764 (1996)
27. Makałowski W, "Alu sequences in the coding regions of mRNA: a source of protein variability", Trends Genet, 10, pp.188~193 (1994)
28. Babu MS, "Association of genetic variants of fibrinolytic system with stroke and stroke subtypes", Gene, 495, pp.76~80 (2012)
29. Lovrecic L, "PAI and TPA gene polymorphisms in multiple sclerosis", Mult Scler, 14, pp.243~247 (2008)
30. Zivković M, "The role of TPA I", D and PAI-14G, Dis Markers, pp.2014, 2014[DOI]
31. Wang HK, "Apolipoprotein E, angiotensin-converting enzyme and kallikrein gene polymorphisms and the risk of Alzheimer’s disease and vascular dementia", J Neural Transm, 113, pp.1499~1509 (2006)
32. Arinami T, "An insertion", deletion polymorphism in the angiotensin converting enzyme gene is associated with both brain substance P contents and affective disorders, 1996, pp.40, 1122~1127
33. Segman RH, "Angiotensin converting enzyme gene insertion", deletion polymorphism: case-control association studies in schizophrenia, major affective disorder, and tardive dyskinesia and a family-based association study in schizophrenia, 2002, pp.114, 310~314
34. De Boer T, "The α2-selective adrenoceptor antagonist org 3770 (mirtazapine, Remeron®) enhances noradrenergic and serotonergic transmission", Hum Psychopharmacol, 10, pp.S107~S118 (1995)
35. de Montigny C, "The effects of mirtazapine on the interactions between central noradrenergic and serotonergic systems", CNS Drugs, 4, pp.13~17 (1995)
36. Haddjeri N, "Noradrenergic modulation of central serotonergic neurotransmission: acute and long-term actions of mirtazapine", Int Clin Psychopharmacol, 10(Suppl 4), pp.11~17 (1995)
37. Nutt DJ, "Tolerability and safety aspects of mirtazapine", Hum Psychopharmacol, 17(Suppl 1), pp.S37~S41 (2002)
38. Kang RH, "Brain-derived neurotrophic factor gene polymorphisms and mirtazapine responses in Koreans with major depression", J Psycho pharmacol, 24, pp.1755~1763 (2010)
39. Hamilton M, "A rating scale for depression", J Neurol Neurosurg Psychiatry, 23, pp.56~62 (1960)
40. Frank E, "Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence", Arch Gen Psychiatry, 48, pp.851~855 (1991)
41. Keller MB, "Past, present, and future directions for defining optimal treatment outcome in depression: remission and beyond", JAMA, 289, pp.3152~3560 (2003)
42. Kim JH, "Reliability and validity of the Korean version of UKU-SERS-Pat in patients with bipolar disorder", Nord J Psychiatry, 62, pp.496~502 (2008)
43. Menashe I, "PGA: power calculator for case-control genetic association analyses", BMC Genet, 9, pp.36~ (2008)
44. Salles FJ, "Localization and regulation of the tissue plasminogen activator-plasmin system in the hippocampus", J Neurosci, 22, pp.2125~2134 (2002)
45. Eskandari F, "Younger, premenopausal women with major depressive disorder have more abdominal fat and increased serum levels of prothrombotic factors: implications for greater cardiovascular risk", Metabolism, 54, pp.918~924 (2005)
46. Chang HS, "Plasminogen activator inhibitor 1 gene polymorphisms and mirtazapine responses in Koreans with major depression", Asia-Pacific Psychiatry, 1, pp.143~151 (2009)
47. Jern C, "Gene polymorphism of t-PA is associated with forearm vascular release rate of t-PA", Arterioscler Thromb Vasc Biol, 19, pp.454~459 (1999)
48. Wong ML, "Research and treatment approaches to depression", Nat Rev Neurosci, 2, pp.343~351 (2001)

관련 논문AI추천